BBI Solutions, the world’s leading independent provider of immuno-diagnostic reagents and contract services, has today announced the acquisition of “Biotez”.
BioTeZ Berlin-Buch GmbH (also including Steffens Biotechnische Analysen GmbH), is a Germany-based manufacturer of reagents and finished tests for the In-Vitro Diagnostics (“IVD”) market, as well as components for the food safety market.
The acquisition of BioTeZ & Steffens-Biotec adds capability and immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier – and therefore a natural partner for its customers.
The addition of BioTeZ’s unique Streptavidin based portfolio enhances BBI’s existing IVD Label portfolio with reagents such as Polystreptavidin, oligonucleotides and poly HRP. Furthermore, the addition of immunoassay development services for ELISA or other formats complements BBI’s existing service offering and customers will benefit from an increased breadth of portfolio and expertise in bringing the next generation of diagnostic tests to market.
The UK-based business, which has manufacturing sites and sales offices across four continents, will integrate the “BioTeZ” & “Steffens-Biotec” manufacturing facilities in Germany, to offer customers unrivalled expertise across all aspects of the immunodiagnostic workflow.
BBI Group Chief Executive Officer, Mario Gualano said:
“This latest acquisition of BioTeZ and Steffens-Biotec further enhances our portfolio and positions BBI as a leading immunoassay reagent supplier. It enables us to provide additional products and services in the fight against the COVID pandemic. The combined research and development capability will provide customers of both BioTeZ and BBI with new, innovative products and a broader portfolio for greater choice.
BBI Solutions is a progressive company with ambitious strategies in place. This development is a great achievement, particularly in these unfamiliar and testing times.”
The combined capability enables BBI to further service high growth disease segments such as cancer, diabetes, and non IVD sectors such as food safety while also enabling BBI to drive geographic expansion for BioTeZ and Steffens-Biotec, which will benefit from a bigger sales force.
Uwe Ahnert, CEO of BioTeZ GmbH, said:
“We are very proud to become part of the BBI family and to be able to reach many more customers worldwide. In doing so, we will be able to support them in the production and development of innovative diagnostics.”